A Europe-based firm that specializes in investing in oncology is currently investing from its third oncology fund of USD 64 million. The firm generally makes investments in Series A, B or C equity rounds; the firm is not interested in seed rounds. The firm typically makes allocations of $3-8 million, and may either lead investments or act as a co-investor alongside a syndicate. The firm is open to oncology opportunities globally but has recently invested primarily in the USA.

The firm is currently focused on oncology therapeutics. The firm will consider any form of therapeutic molecule in oncology, including small molecules, antibodies or new technologies such as cell therapies. The firm generally invests at the late preclinical stage, from 6-12 months pre-IND, but is also interested in companies with Phase I or Phase II assets.

The firm places high importance on the management team’s scientific rigor and industry experience; the firm prefers to work with entrepreneurs who have led biotech companies previously. The firm also considers the strength of the investor syndicate and their alignment of interests.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital company based the southeast USA manages several funds, with its most recent fund having had its first close in 2017. The firm looks to provide up to $3-4 million of preferred equity capital in the initial round and up to $6 million over the life of the investment. The firm is very flexible in terms of period to exit but generally looks to exit in around 5 years. The firm will consider companies globally.

The firm is currently looking for companies developing Therapeutics and Medical Technology. Within therapeutics, which is the firm’s primary focus, companies with an asset anywhere from pre-clincal with positive animal data to phase II will be considered. The firm is generally open to all technology types and indications with the exception of wound care and psychiatry. Within devices, the firm is currently looking for market approved product with early revenue; however, devices are not an investment priority at present. The firm is looking for companies targeting true un-met medical needs where either no treatment currently exists or the existing standard of care is wrought with side-effects and other impediments to quality care.

The firm does not have any specific requirement for a firm’s management team although they are an active investor looking to take a seat on the company’s board. The firm generally tends to lead or co-lead investments into selected companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A hedge fund sponsor with offices in New York, Hong Kong and London currently manages a total of over $30 billion in total. The firm invests primarily in public and private equity securities from a wide range of industries globally. The firm prefers to participate in a financial round of at least $40 million, and has no hard stops on phase of development. The group has the potential of allocating $100 million in equity over the life of investment in companies with at least $400 million valuation.

The firm invests across several industry sectors. In life sciences, the firm is agnostic to subsectors and therapeutic areas but is currently interested in genomics and biotech therapeutics. The firm looks for late stage platform technologies with significant market potential, and rarely invest in companies with a single therapeutic asset.

The firm is seeking competent and experienced management teams with proven business model.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A China-based enterprise specialized in blood purification is seeking to collaborate with early stage businesses with advanced technology and mutual cooperation on China-USA market that are a strategic fit for its pipeline and marketing resources. Equity investment size can be flexible which is mostly regarding strategic collaboration but typically ranges from US$1-5 million. The firm can also consider collaborative research, licensing, and merger and acquisition. The firm is looking for new opportunities globally with a focus on the US.

The firm is interested in consumables and medical devices in the hematology, renal diseases and liver diseases fields. The firm prefers post-prototype products with preclinical and clinical validation. Products should have a strategic angle with the firm’s pipeline.

The firm is looking for experienced management teams with sector expertise. The firm is interested in distribution rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The venture capital arm of a global pharmaceutical firm invests in early stage ideas with breakthrough technologies addressing major unmet medical needs. The firm seeks to make equity investments in Seed and Series A/B rounds with an ultimate possibility of acquisition. The firm has a global mandate and is currently seeking new investment opportunities.

The firm is currently seeking to invest in early to mid-stage repurposed drugs, repositioned drugs, combination therapies, and new delivery technologies and devices for old drugs. In terms of indications, the firm is focused on CNS and respiratory diseases. The firm will prioritize 505(b)(2) opportunities.

The firm seeks companies with a strong and experienced management team. The firm may take a board seat/board observer rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm based in Paris, France has a venture team that currently has €400M AUM. The firm mainly provides equity financing and may provide convertible loans as follow-on investments. The firm typically makes an initial investment of up to €2-3M, and up to €8M over the life of the investment, which can be start as early as seed stage. The firm preferably invests in European-based companies, and seeks to make about 2 allocations every year in the life sciences area (minority stakes).

The firm remains opportunistic in the life sciences, with a focus on drug development and medical devices. The firm is agnostic in terms of subsectors, indications and stage. Currently, the firm is active in many subsectors.

The firm seeks to acquire minority stakes in its portfolio companies. The firm is looking for companies with a talented and entrepreneurial management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity group with offices on the US East and West Coasts has over $1 billion in assets under management, and is investing from a third fund of over $500 million. The firm makes both venture-stage and growth-stage equity investments, which are typically in the $10-30 million range. The firm primarily invests in North America and the European Union but may also consider opportunities in the Middle East.

The firm invests in biotechnology, medical technology, diagnostics, healthcare services, and healthcare IT. The firm is generally agnostic regarding indications. The firm invests at a range of stages, from development through to profitability, but prefers to back technologies that have attained proof of concept data.

The firm invests in both pre-revenue companies and post-revenue companies. The firm typically leads or co-leads investments, and prefers to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com